Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Ravid Straussman(Weizmann Institute of Science), Todd R. Golub(Broad Institute), Margaret Mongare(Eli and Edythe Broad Foundation), Joshua Gould(Eli and Edythe Broad Foundation), Teppei Morikawa(Dana-Farber Cancer Institute), Roger S. Lo(University of California, Los Angeles), Keith T. Flaherty(Cancer Research Center), Jennifer A. Wargo(The University of Texas MD Anderson Cancer Center), Michal Barzily-Rokni(Shaare Zedek Medical Center), Dennie T. Frederick(Broad Institute), Kevin Shee(Broad Institute), Zachary A. Cooper(AstraZeneca (Singapore)), Shuji Ogino(Broad Institute), Antoni Ribas(University of California, Los Angeles), Paul B. Chapman(Memorial Sloan Kettering Cancer Center), Zhi Rong Qian(Dana-Farber Cancer Institute), David B. Solit(Memorial Sloan Kettering Cancer Center), Jinyan Du(Guangzhou University of Chinese Medicine), Ashli Davis(Eli and Edythe Broad Foundation)
Cited by 1,742
Related Papers
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
|Proceedings of the National Academy of Sciences|2005|56.5k
Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring
|Science|1999|11.6k
PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes
|Nature Genetics|2003|10.6k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k